低浓度阿托品滴眼液与安慰剂对儿童近视发病率的影响:LAMP2随机临床试验
这项在中文大学眼科中心开展的随机、安慰剂对照、双盲试验纳入474名4至9岁非近视儿童,随机分为0.05%阿托品组(160人)、0.01%阿托品组(159人)和安慰剂组(155人),每晚双眼滴眼一次,持续2年。结果显示,0.05%阿托品组2年累积近视发病率显著低于安慰剂组(差异24.6%,95%CI 12.0%-36.4%),快速近视漂移比例也显著更低(差异28.9%,95%CI 16.5%-40.5%);0.01%阿托品组与安慰剂组无显著差异。结论认为0.05%阿托品可降低近视发病率和快速近视漂移比例,但需进一步研究验证。
要点
- 4至9岁非近视儿童每晚使用0.05%阿托品滴眼液2年,近视累积发病率显著低于安慰剂组。
- 0.05%阿托品组快速近视漂移比例显著低于安慰剂组,0.01%阿托品组与安慰剂组无显著差异。
- 畏光是最常见不良事件,第二年0.05%组报告率为12.9%。
核心结论
- 在4至9岁无近视儿童中,与安慰剂相比,每晚使用0.05%阿托品滴眼液可使2年近视发病率显著降低,快速近视漂移比例也显著降低。
- 0.01%阿托品与安慰剂之间在2年累积近视发病率或快速近视漂移比例上无显著差异。
- 需要进一步研究来重复这些发现、了解这是延迟还是预防近视,并评估长期安全性。
研究设计与样本
- 随机、安慰剂对照、双盲试验,在中文大学眼科中心开展,纳入474名4至9岁非近视儿童,睫状肌麻痹等效球镜在+1.00 D至0.00 D之间,散光小于-1.00 D。
- 参与者随机分为0.05%阿托品组(n=160)、0.01%阿托品组(n=159)和安慰剂组(n=155),每晚双眼滴眼一次,持续2年。
- 首位入组参与者于2017年7月11日开始治疗,最后一位参与者于2020年6月4日入组,末次随访日期为2022年6月4日。
主要发现
- 474名随机化患者平均年龄6.8岁,女性占50%,353名(74.5%)完成试验。
- 2年累积近视发病率:0.05%阿托品组28.4%(33/116),0.01%阿托品组45.9%(56/122),安慰剂组53.0%(61/115)。
- 2年快速近视漂移比例:0.05%阿托品组25.0%,0.01%阿托品组45.1%,安慰剂组53.9%。
- 与安慰剂组相比,0.05%阿托品组2年累积近视发病率差异为24.6%(95%CI 12.0%-36.4%),快速近视漂移比例差异为28.9%(95%CI 16.5%-40.5%)。
- 与0.01%阿托品组相比,0.05%阿托品组2年累积近视发病率差异为17.5%(95%CI 5.2%-29.2%),快速近视漂移比例差异为20.1%(95%CI 8.0%-31.6%);0.01%阿托品组与安慰剂组在2年累积近视发病率或快速近视漂移比例上无显著差异。
关键数值与推荐
- 主要结局为2年累积近视发病率(任一眼睫状肌麻痹等效球镜至少-0.50 D)和快速近视漂移参与者百分比(等效球镜近视漂移至少1.00 D)。
- 畏光是最常见不良事件,第二年0.05%阿托品组报告率为12.9%,0.01%阿托品组为18.9%,安慰剂组为12.2%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究来重复这些发现、了解这是延迟还是预防近视,并评估长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early onset of myopia is associated with high myopia later in life, and myopia is irreversible once developed. OBJECTIVE: To evaluate the efficacy of low-concentration atropine eyedrops at 0.05% and 0.01% concentration for delaying the onset of myopia. DESIGN, SETTING, AND PARTICIPANTS: This randomized, placebo-controlled, double-masked trial conducted at the Chinese University of Hong Kong Eye Centre enrolled 474 nonmyopic children aged 4 through 9 years with cycloplegic spherical equivalent between +1.00 D to 0.00 D and astigmatism less than -1.00 D. The first recruited participant started treatment on July 11, 2017, and the last participant was enrolled on June 4, 2020; the date of the final follow-up session was June 4, 2022. INTERVENTIONS: Participants were assigned at random to the 0.05% atropine (n = 160), 0.01% atropine (n = 159), and placebo (n = 155) groups and had eyedrops applied once nightly in both eyes over 2 years. MAIN OUTCOMES AND MEASURES: The primary outcomes were the 2-year cumulative incidence rate of myopia (cycloplegic spherical equivalent of at least -0.50 D in either eye) and the percentage of participants with fast myopic shift (spherical equivalent myopic shift of at least 1.00 D). RESULTS: Of the 474 randomized patients (mean age, 6.8 years; 50% female), 353 (74.5%) completed the trial. The 2-year cumulative incidence of myopia in the 0.05% atropine, 0.01% atropine, and placebo groups were 28.4% (33/116), 45.9% (56/122), and 53.0% (61/115), respectively, and the percentages of participants with fast myopic shift at 2 years were 25.0%, 45.1%, and 53.9%. Compared with the placebo group, the 0.05% atropine group had significantly lower 2-year cumulative myopia incidence (difference, 24.6% [95% CI, 12.0%-36.4%]) and percentage of patients with fast myopic shift (difference, 28.9% [95% CI, 16.5%-40.5%]). Compared with the 0.01% atropine group, the 0.05% atropine group had significantly lower 2-year cumulative myopia incidence (difference, 17.5% [95% CI, 5.2%-29.2%]) and percentage of patients with fast myopic shift (difference, 20.1% [95% CI, 8.0%-31.6%]). The 0.01% atropine and placebo groups were not significantly different in 2-year cumulative myopia incidence or percentage of patients with fast myopic shift. Photophobia was the most common adverse event and was reported by 12.9% of participants in the 0.05% atropine group, 18.9% in the 0.01% atropine group, and 12.2% in the placebo group in the second year. CONCLUSIONS AND RELEVANCE: Among children aged 4 to 9 years without myopia, nightly use of 0.05% atropine eyedrops compared with placebo resulted in a significantly lower incidence of myopia and lower percentage of participants with fast myopic shift at 2 years. There was no significant difference between 0.01% atropine and placebo. Further research is needed to replicate the findings, to understand whether this represents a delay or prevention of myopia, and to assess longer-term safety. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR-IPR-15006883.
引用
- Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023. PMID: 36786791. doi:10.1001/jama.2022.24162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。